| Name | Title | Contact Details |
|---|
Since 1919, Mossberg has been the leader in introducing important design breakthroughs to the firearm industry. Many product features pioneered by Mossberg are now the standards by which all modern firearms are judged. Never content with the status quo, our men and women constantly strive to improve and update the capabilities of all Mossberg® products. In accomplishing this goal, we recognize that each improvement is a part of the "Shooting System" approach and most are designed to fit the shotgun you bought years ago. Our design and innovative edge is truly changing the way shooters use shotguns and rifles. We are particularly proud that our Mossberg® pump shotguns are the only shotguns purchased by the United States government that meet or exceed Mil-S-3443 specifications. It is this basis of unquestionable quality that drives Mossberg® to bring reliable, well-built shooting systems to you at an affordable price. The shooting sports have been an American tradition for generations. Today, thousands of sportsmen and sportswomen focus their energy on the betterment of the shooting sports by participating in national and local organizations. We sincerely appreciate these efforts, and we salute all future members for continuing our proud heritage.
Rockhopper is a Denver, CO-based company in the Business Services sector.
Spartan Printing Incorporated is a Lansing, MI-based company in the Business Services sector.
Innovative Design Solutions is a Troy, MI-based company in the Business Services sector.
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.